Elanco Animal Health Inc (ELAN) · Aug 5, 2026 · Company update

Profit beat and outlook rises as product momentum broadens

Profit beat and outlook rises as product momentum broadens

The quarter cleared both the outside bar and Elanco’s own outlook. Adjusted EPS of $0.34 exceeded the published consensus of about $0.27, while revenue of $1.368 billion topped the roughly $1.31 billion expectation. It also surpassed the company’s prior Q2 ranges for revenue ($1.300-$1.325 billion), adjusted EBITDA ($240-$260 million) and adjusted EPS ($0.25-$0.28). The result was not just accounting-driven: organic constant-currency revenue rose 8%, led by 11% Pet Health growth and 12% cattle growth. (Second Quarter Results; Financial Guidance)

MetricQ2 2026 actualQ2 2025Prior company Q2 outlook / published expectation
Revenue$1.368B$1.241B$1.300-$1.325B / ~$1.31B consensus (Second Quarter Results; Financial Guidance)
Organic constant-currency revenue growth8%—4%-6% prior outlook (Second Quarter Results; Q2 Guidance)
Adjusted EBITDA$288M$238M$240-$260M prior outlook (Adjusted EBITDA reconciliation; Q2 Guidance)
Adjusted EBITDA margin21.2%19.2%— (Adjusted EBITDA reconciliation)
Adjusted EPS$0.34$0.26$0.25-$0.28 prior outlook / ~$0.27 consensus (Adjusted EPS reconciliation; Q2 Guidance)
Full-year revenue guidance$5.090-$5.140B—Raised from $5.010-$5.085B (2026 Full Year Guidance)
Full-year adjusted EBITDA guidance$1.010-$1.035B—Raised from $975M-$1.005B (2026 Full Year Guidance)
Full-year adjusted EPS guidance$1.10-$1.16—Raised from $1.03-$1.09 (2026 Full Year Guidance)

The guidance raise makes the beat more consequential. Full-year revenue guidance rose $67.5 million at the midpoint, adjusted EBITDA rose $32.5 million, and adjusted EPS rose $0.07. Importantly, the company lifted its underlying organic-growth floor to 6%-7% from 5%-7%, rather than relying only on the approximately $60 million foreign-exchange tailwind; expected adjusted gross-margin expansion also improved to 50 basis points from 40 basis points. (2026 Full Year Guidance)

Margins and deleveraging strengthened alongside growth. Adjusted gross margin expanded 80 basis points year over year in Q2, ahead of management’s own expectation, while adjusted EBITDA margin expanded 200 basis points. Net debt fell to $3.159 billion from $3.335 billion at March 31, and net leverage reached 3.1x from 3.5x. That addresses a key standing concern for a company still carrying substantial debt. (Adjusted Gross Profit reconciliation; Adjusted EBITDA reconciliation; Net Debt reconciliation)

The main qualification is that adjusted profit remains far above GAAP profit, and spending is rising. GAAP EPS was only $0.11, versus $0.34 adjusted, with intangible amortization alone accounting for $0.27 per share of exclusions. Marketing, selling and administrative expense rose 12%, and Elanco expects Q3 operating expenses to increase about 10% in constant currency as it funds product launches. Those costs are deliberate growth investment, but they mean the improved margin trajectory must continue to offset higher commercial spending. (Income Statement; Adjusted EPS reconciliation; Third Quarter Guidance)

Original filing on SEC EDGAR

More Elanco Animal Health Inc news

Profit beat and outlook rises as product momentum broadens | ELAN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.